Boryung receives approval for additional Indication of Stogar tablets

Published: 2013-08-23 06:57:00

Updated: 2013-08-23 06:57:00

Boryung Pharmaceutical Co. announced today that it has received approval from the Ministry of Food and Drug Safety for gastro-esophagegus reflux disease (GERD) as an additional indication of Stogar (lafutidine) tablets, a second generation H2 receptor antagonist developed by UCB Japan.

In a lo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK